Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft Versus Host Disease

NCT06233110 is registered in ClinicalTrials.gov with Stefanie Sarantopoulos, MD, PhD. as lead sponsor.

NCT NCT06233110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06233110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft Versus Host Disease
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Phase
Phase 1
Overall status
Recruiting
Start date
October 29, 2025
Completion date
July 1, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease